Volume 22 • Issue 02 • 2018
registration trail correlate with findings of other
studies using this antigen vaccine combination
(H-gal-GP and H11) (Le Jambre et al. 2008). Field
studies conducted over 11 months under natural
grazing were conducted in South Africa and gave
similar protection levels to what was found here
(Smith et al. 2001).
This H-gal-GP, H-11 containing vaccine was
registered in 2014 in Australia and is marketed
commercially as Barbervax®. In South Africa,
the registration for Wirevax® was obtained in
November 2016.
Wirevax was launched to a small group of sheep
farmers with known worm resistance problems
in their flocks. The results seen are comparable
with the studies mentioned